Oryzon Genomics Advances Vafidemstat into Phase III

Oryzon Genomics SA (ES:ORY) has released an update.

Oryzon Genomics S.A. has announced the successful completion of their End-of-Phase II meeting with the FDA for vafidemstat in treating Borderline Personality Disorder, with positive feedback supporting the advancement to the Phase III PORTICO-2 trial. The FDA has acknowledged the potential of vafidemstat as a treatment for agitation-aggression in BPD and has accepted the STAXI-2 Trait anger scale as the primary assessment criterion for the upcoming trial.

For further insights into ES:ORY stock, check out TipRanks’ Stock Analysis page.